Blog

qordata thought leaders and subject matter experts share their insights and experiences

Ned Mumtaz
Written By
Ned Mumtaz
July 26, 2017
0 Comments

This blog follows from Part I, where we shared advice from Compliance/Transparency professionals from Shire Pharmaceuticals, Porzio Bromberg and Merz North America on how to make your datasets more robust and CMS compliant. Treat Your Data Like Someone At The CMS Or DOJ Would: Compliance teams often focus on the supply side of spend data, i.e. presentation of their individual submissions. What recedes to the backburner in such cases is the extent of scrutiny, the search for common data culprits (e.g. missing NPIs) and the questionable records that interest authorities in CMS and the DoJ. Establish a habit of treating your data to the same scrutiny regulators would. Don’t assume that just because your numbers make sense internally, they will […]

Ned Mumtaz
Written By
Ned Mumtaz
July 25, 2017
0 Comments

In our most recent webinar, we explored how data management processes differ in pharmaceuticals across USA. Interestingly, processes are standardized across the most compliant and transparent medical drug and device manufacturers. Based on this, we must ask: Is there one best way of going managing and leveraging spend analytics data? Yes, accounting for differences brought in by internal policy. The processes described by our panelists, April Pierce, Chrissy Bradshaw and Elizabeth Bodine from Shire Pharmaceuticals, Porzio Bromberg, and Merz North America, respectively, had quite a few steps in common: Information Sharing Must Be Proactive: This is important. Your audience, according to Elizabeth Bodine, need to know what they’re looking for. It could be performance figures, information related to KOL or […]

Jeanine Sieja
Written By
Jeanine Sieja
July 20, 2017
0 Comments

Do pharmaceuticals need a compass to decide their next headquarter or research center? Yes, but not quite the one you’d expect. The right compass is called qordata Compliance Insights, an analytics tool that has collected, analyzed and gleaned the most useful from the latest CMS data by geography. What do these insights tell you about the best location for your pharma investment? Zooming In Is ‘Born in America’ a prerequisite for being featured in the list of highest spenders? Not for medical drug and device companies. The top companies of foreign origin by spend were responsible for a total of $643.54 million between 2015-2016. That’s 7.87% of the total spend reported in 2016. This amount came from 108 (127 if […]

Ned Mumtaz
Written By
Ned Mumtaz
July 17, 2017
0 Comments

Regulator visitors to this blog will know how important it is for qordata to get facts about pharmaceutical spend data right. We would go so far as to say that protecting the sanctity, validity and relevance of this data has a sacred status with us. But before data can be all this, it needs to undergo a number of internal and external processes. Unlike many of the technically-sophisticated and complex processes needed for onward submission, one of the most basic, and most critical requires neither. That process is: Giving data the right context. In a webinar-cum-discussion I hosted last month, I asked my panelists about some of the challenges they face in their organizations’ compliance programs. All three panelists Elizabeth […]

Upcoming Event

11th Annual Forum on Transparency & Aggregate Spend

14 Aug to 16 Aug, 2017
8:00 am To 6:00 pm EST
DETAILS

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

Get Answer
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.